Business Context and Reporting Period
Company: Alterity Therapeutics Limited (a development stage enterprise)
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Month of December 2024
Principal Executive Office: Level 14, 350 Collins Street, Melbourne, Victoria 3000, Australia
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. As a development stage enterprise, the document serves as a notification regarding unquoted securities rather than a financial results report.
Material Changes
No material financial changes versus a prior comparable period are disclosed in this filing. The document primarily incorporates by reference into existing Registration Statements on Form S-8 and Form F-3.
Guidance, Outlook, and Risks
Management Commentary: None provided in this specific filing.
Risks and Contingencies: The filing includes Exhibit 99.1, a "Notification regarding unquoted securities," but does not elaborate on specific risks or contingencies within the text provided.
Investor Verification Checklist
- Verify the details of the "unquoted securities" referenced in Exhibit 99.1.
- Review the referenced Registration Statements (Form S-8 and Form F-3) for broader context on capital structure.
- Confirm the company's status as a development stage enterprise and its current cash runway via recent Form 20-F filings.